VivoSeq
Other

Cognitive Dysfunction

1

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Cognitive Dysfunction is an early-stage landscape with 1 program across 1 company. The most active players are Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

63/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Donanemab

Eli Lilly

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

20

clinical trials

Unknown status8 · 40%
Completed5 · 25%
Recruiting4 · 20%
Withdrawn2 · 10%
Terminated1 · 5%

Clinical Trials

Trial Activity

20 trials

Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics
Recruiting·FFayoum University·Phase 1·NCT06702488·58 enrolled
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Recruiting·UUniversity of California, Irvine·Phase 2·NCT07447050·24 enrolled
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
Recruiting·MMassachusetts General Hospital·Phase 2·NCT06136546·100 enrolled
A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07589595·350 enrolled
Ulinastatin Improves Post-Cardiac Surgery Cognitive Dysfunction
Completed·—·N/A·NCT06268249·7,065 enrolled
Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
Completed·UUniversity Health Network, Toronto·Phase 3·NCT02423824·21 enrolled
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
Completed·—·Phase 1·NCT02517502·24 enrolled
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
Completed·YYale University·N/A·NCT00935493·154 enrolled
Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
Completed·WWake Forest University Health Sciences·Phase 1·NCT01151670·18 enrolled
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
Terminated·SSun Yat-sen University·Phase 3·NCT04395339·51 enrolled
A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid
Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06234462
Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery
Withdrawn·—·N/A·NCT01186289
Cognitive Dysfunction Following Cardiac Surgery
Unknown status·—·Phase 4·NCT02767713·171 enrolled
Long-term Consequences of Neuroimaging and Perceived Cognitive Dysfunction in oPRES
Unknown status·—·N/A·NCT05140850·500 enrolled
Lidocaine on Early Cognitive Dysfunction in Shoulder Arthroscopy
Unknown status·—·Phase 2·NCT04634656·80 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)